

Review Article

Ventilator-associated pneumonia (VAP)-An overview

Dr. Kotgire. Santosh. A

Associate Professor, Department of Microbiology, Indian institute of medical sciences and research, Badnapur, Jalna, Maharashtra, India

***Corresponding author**

Dr. Kotgire. Santosh. A

Email: santosh_kots2001@yahoo.com

Abstract: Patients in the intensive care unit (ICU) are at increase risk for dying not only from their critical illness but also from secondary processes such as nosocomial pneumonia. Pneumonia is most common infection in ICU compared with those in hospital wards and risk of pneumonia increases considerably in patients on mechanical ventilation were it termed as Ventilator-associated pneumonia (VAP). Ventilator-associated pneumonia represents a major health problem not only in terms of excess morbidity, mortality and personal distress but also contribute to significant economic loss. The incidence of VAP ranges from 10-65% depending on the definitions ,severity of illness ,type of patients studied, type of ICU/or hospital, prophylactic antibiotics administration, the techniques, and criteria used for diagnosis and can reach 78% in some specific settings or when lung infection is caused by high risk pathogens. The predominant organisms responsible for infection are Staphylococcus aureus, Pseudomonas aeruginosa, and Enterobacteriaceae, but etiologic agents widely differ according to the population of patients in an intensive care unit, duration of hospital stay, and prior antimicrobial therapy .Choosing appropriate therapy for VAP include knowledge of organisms likely to be present, local resistance patterns within the ICU, a rational antibiotic regimen, and a rationale for antibiotic de-escalation or stoppage.

Keywords: Intensive care unit (ICU); nosocomial infection; ventilator-associated pneumonia (VAP)

INTRODUCTION

“It seems a strange principle to enunciate as the very requirement in a hospital that it should do the sick no harm” quoted by Florence nightingale in 1863 holds true even to this day. The hospital while fulfilling its role as health care institute, sometimes present its patients with unwanted gifts of hospital-acquired infection.

Hospital acquired infection (HAI) or Nosocomial infection(NI) is defined as the infection acquired by a patient as a result of hospitalization or contact with the hospital environment, that were neither present nor incubating at the time of the patient’s visit or admission to the hospital [1,2,3,4].

Kollef MH 1965[5] and Vincent J *et al.*; 1995 [6] observed that the common types of nosocomial infection encountered in any institution depends on a number of factors including the type of hospital or ward, the age, underlying illnesses and/or comorbid conditions of the patients, the severity of illness of individual cases and the treatment instituted.

In the study of El-ebiary M *et al.*; 1993[7] .found the most common HAI are urinary tract

infection, respiratory infection, blood stream infection, skin and surgical site infections.

According to the surveillance data from the National Nosocomial Infection Surveillance System (NNIS) of the Center for Disease Control and Prevention (CDC), Hospital acquired pneumonia (HAP) or Nosocomial pneumonia (NP) is the most common infection in the intensive care units (ICUs), second most common hospital infection and leading cause of death among hospital acquired infection [8,9,10].

Nosocomial pneumonia or hospital acquired pneumonia (HAP) is defined as the parenchymal lung infection occurring ≥ 48 hrs after the admission that was neither present or incubating at the time of admission , incidence of HAP varies from 9-78% depending on severity of illness, type of patients studied the techniques and criteria used for the diagnosis of pneumonia[1,11,12,13,14].

The occurrence of pneumonia is high in the intensive care units(ICU) mainly because of high utilization of invasive procedure like mechanical ventilation also patients admitted to ICUs are critically ill have deranged vital functions requiring

interventional procedure which results in breach in natural barriers providing environment for infection resulting in hospital acquired pneumonia [15,16].

Hospital acquired pneumonia is most common nosocomial infection reported among ventilated patients admitted in ICU where it is termed as “ventilator associated pneumonia” (VAP) [1, 5, 6].

Ventilator associated pneumonia (VAP) refers to pneumonia developing in mechanically ventilated patients more than 48 hrs after tracheal intubation or tracheostomy. The incidence of VAP ranges from 10-65% and can reach 78% in some specific settings or when lung infection is caused by high risk pathogens [15, 16, 17, 18].

In contrast to infections of more frequently involved organs (e.g. urinary tract, skin) for which mortality is low, ranging from 1 to 4% the mortality associated with VAP ranges from 20-40% [19, 20].

Conceptually VAP is defined as an inflammation of lung parenchyma caused by infectious agents not present or incubating at the time mechanical ventilation was started [20].

It is conclusively shown that prior to the development of VAP, the pathogenic organisms the source of which could be exogenous or endogenous colonize trachea. Some studies show oropharynx to be the source of colonization, while other shows the stomach to be the source of colonization [20, 21].

The primary risk factor for development of VAP is mechanical ventilation with its requisite endotracheal intubation or tracheostomy.

VAP is complex and multifactorial and clinical criteria for the suspicion of VAP is usually seen in patients who are mechanically ventilated for more than 48 hrs and includes as per according to American Thoracic Society guidelines [4].

New or persistent or progressive radiographic infiltration plus two of at least of following:-

1. Temperature $\geq 38^{\circ}\text{C}$ or $\leq 35^{\circ}\text{C}$.
2. Total Leukocyte count $\geq 10000\text{mm}^3$ or $\leq 4000\text{mm}^3$.
3. Purulent tracheal secretions.

In ICU patients especially those who are intubated, the signs of pneumonia are relatively subtle and thus the diagnosis often is relatively complex. Clinical criteria lack both sensitivity and specificity moreover there are many causes that mimic these clinical manifestations of VAP leading to a high rate of

misdiagnosis and unnecessary misuse of antibiotics [23, 24, 25].

Thus microbiological diagnosis achieves major importance in the diagnostic strategy of ventilator associated pneumonia. The method of choice for laboratory diagnosis, whether invasive bronchoscopic methods such as protected specimen brush (PSB) or bronchoalveolar lavage (BAL), or non-invasive endotracheal aspirate remains controversial [24, 25]. Many studies have shown that performance of invasive and non-invasive techniques have varied considerably and no technique could consistently be shown to achieve a superior diagnostic yield as compared with another, thus there is no “gold standard method” for diagnosis of VAP [2, 5, 23,24].

In the intubated patients with suspected VAP lower airway secretions are easily available with routine endotracheal aspiration and is considered adequate specimen when strict definitional criteria (organisms on gram stain and fewer than 10 squamous epithelial cells per low power field and more than 25 neutrophils per high power field) [5,7,9].

Advantage of non-invasive techniques includes less invasiveness, less compromise of oxygenation, ventilation and respiratory mechanics during the procedure, less likely to induce arrhythmias [7, 9].

ETA is least expensive, most readily available, requires least experience and easily repeatable and many authors have concluded that the diagnostic accuracies of non-invasive and invasive techniques are similar and comparable [22, 23].

Additionally, non quantitative or qualitative culture of ETA are sensitive but not specific method for evaluating etiological agents because many patients are commonly colonized pathogenic organisms and mere recovery of potential pathogen from an ETA cannot determine whether the organism is pathogen or simply colonizing or contaminant [22,24].

To avoid the problem of diagnosis and over treatment by separating colonizers from pathogenic organism many studies have suggested quantitative culture of ETA should be used to avoid false positive results [15, 16].

As per American thoracic society guidelines VAP can be studied as early onset i.e. (occurring <5 days or within 96 hrs of mechanical ventilation) and late onset (occurring > 5 days or after 96 hrs of mechanical ventilation) [4].

The causative organisms vary according to the patient’s demographics in ICU, methods of diagnosis,

the duration of hospital and ICU stay, and the antibiotic policy. Several studies have shown that aerobic gram negative bacteria are the most common pathogens responsible for VAP. The most common aerobic gram negative bacteria are *Pseudomonas aeruginosa*, *E-coli*, *Klebsiella pneumoniae*, *Acinetobacter* spp, *Enterobacter* spp and less commonly *Proteus* spp, *Citrobacter* spp, *H.influenza* although many studies have also reported along with aerobic gram negative bacteria the dominance of gram positive bacteria especially *Staphylococcus aureus* in causing VAP is well documented other gram positive bacteria responsible for VAP are *Streptococcus pneumoniae*, *Staphylococcus epidermidis*, *Enterococci* spp, *Streptococci* spp [2,5,6,8,18].

Overall rate of positive blood culture in VAP ranges from 8-20% and some studies reports that bacteremia in this patients is not always related to pulmonary infection and may have other additional source of infection [5,7,9]. The American Thoracic Society guidelines for hospital-acquired pneumonia recognize that blood cultures may be of value both to isolate an etiologic pathogen and also to define the severity of illness [4].

Laboratory investigations of microbial cause are important because in absence of such identification of organisms, antibiotic therapy may not be optimal. At the same time increasing antibiotic resistance among the bacterial pathogens associated with VAP [9, 10].

There is increasing trend of multiple drug resistant (MDR) isolates in ICU setup such as Extended spectrum β -lactamases (ESBL) by *Enterobacteriaceae*, Methicillin resistant *Staphylococcus aureus* (MRSA), Metallo- β lactamases (M β L) producing *Pseudomonas aeruginosa*, *Acinetobacter* spp which considerably increases morbidity, mortality and increase in days of mechanical ventilation among the hospitalized patients [11,13,14].

The occurrence of MDR in ICU and hospital environment poses not only therapeutic problem but also serious concern for infection control management [2, 4, 5].

The major goals in treating the VAP should emphasize on early and appropriate antibiotic in adequate doses based on microbiologic culture and clinical response of patient. The literature shows that inadequate antibiotics for 48-72 hrs. Is associated with increase morbidity and mortality and several studies shown that appropriate antimicrobial treatment of patients with VAP significantly improves the outcome [8, 9, 12].

Therefore, knowledge about the commonest etiological pathogens causing VAP and their antimicrobial susceptibility pattern at the institute level will definitely useful in formulating its antibiotic policy and optimal management of patients. A local surveillance program at each centre is essential as knowledge of local resistant patterns is vital for selecting appropriate agents for treating infections.

CONCLUSION

Occurrence of MDR in the ICU and hospital environment poses not only therapeutic problem but also serious concern for infection control management. A local surveillance program at each centre is essential as knowledge of local resistant patterns is vital for selecting appropriate agents for treating infection.

Lastly exact bacteriological profile and antibiotic susceptibility pattern of ventilator associated pneumonia in an ICU should be known to plan strategies for treatment and better patient's management.

REFERENCES:

1. Speller DCE; Hospital-acquired infections. Chapter 3.9. In Topley and Wilson's Principles of Bacteriology, Virology and Immunology. 8th Edition Vol 3 Bacterial Diseases. Parker MT, Collier LH, Smith G 1990:141-169.
2. World health organization (WHO) Guidelines on prevention and control of Hospital-Associated Infection. Published by regional office for South-East Asia. January 2002.
3. Chastre J, Fagon JY; Ventilator-associated pneumonia. *Am J Respir Crit Care Med*.2002; 165(7):867-903.
4. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. *Am J Respir Crit Care Med* 1996; 153:1711–1725.
5. Kollef MH; Ventilator-associated pneumonia. *JAMA* 1993; 270: 1965-70.
6. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH *et al.*; The prevalence of nosocomial infection in intensive care units in Europe: Results of European prevalence of infection in intensive care (EPIC) study. *JAMA* 1995;274(8): 639-644.
7. El-ebiary M, Torres A, Gonzalez J; Diagnosis of ventilator associated (VA) pneumonia: Diagnostic value of quantitative cultures of endotracheal aspirates (EA). *Am Rev Respir Dis* 1993; 148: 1552-57.
8. Marquette CH, Georges H, Waller F, Ramon P, Saulnier F, Neviere R *et al.*; Diagnostic efficiency of endotracheal aspirates with quantitative bacterial

- cultures in incubated patients with suspected pneumonia. *Am Rev Respir Dis* 1993; 148(1):138-44.
9. National Nosocomial Infections Surveillance (NNIS) System. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990–May 1999, issued June 1999. *Am J Infect Control* 1999; 27:520–532.
 10. Centers for Disease Control and Prevention. Guidelines for prevention of nosocomial pneumonia. Centers for Disease Control and Prevention. *MMWR* 1997; 46:1–79.
 11. Fartoukh M, Maître B, Honoré S, Cerf C, Zahar JR, Brun-Buisson C; Diagnosing Pneumonia during Mechanical Ventilation. The Clinical Pulmonary Infection Score Revisited. *Am J Respir Crit Care Med* 2003; 168(2): 173–179.
 12. Rello J, Ausina V, Ricart M, Castella J, Prats G; Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. *Chest* 1993; 104(4):1230–1235.
 13. Chevret S, Hemmer M, Carlet J, Langer M; Incidence and risk factors of pneumonia acquired in intensive care units. Results from a multicenter prospective study on 996 patients. European Cooperative Group on Nosocomial Pneumonia. *Intensive Care Med* 1993; 19:256–264.
 14. Cross AS, Roup B; Role of respiratory assistance devices in endemic nosocomial pneumonia. *Am J Med* 1981; 70:681–685.
 15. Langer M, Mosconi P, Cigada M, Mandelli M; Long-term respiratory support and risk of pneumonia in critically ill patients. Intensive Care Unit Group of Infection Control. *Am Rev Respir Dis* 1989; 140:302–305.
 16. Craven DE, Steger KA; Nosocomial pneumonia in mechanically ventilated adult patients: epidemiology and prevention in 1996. *Semin Respir Infect* 1996; 11:32–53.
 17. Celis R, Torres A, Gatell JM, Almela M, *et al.*; Nosocomial pneumonia. A multivariate analysis of risk and prognosis. *Chest* 1988; 93: 318–324.
 18. Fagon JY, Chastre J, Domart Y, Trouillet JL, Pierre J, Darne C *et al.*; Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. *Am Rev Respir Dis* 1989; 139(4):877–884.
 19. Bell RC, Coalson JJ, Smith JD, Johanson WG; Multiple organ system failure and infection in adult respiratory distress syndrome. *Ann Intern Med* 1983; 99:293–298.
 20. Torres A, Aznar R, Gatell JM, Jiménez P, González J, Ferrer A *et al.*; Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. *Am Rev Respir Dis* 1990; 142(3):523–528.
 21. Craven DE, Kunches LM, Kilinsky V, Lichtenberg DA, Make BJ, McCabe WR; Risk factors for pneumonia and fatality in patients receiving continuous mechanical ventilation. *Am Rev Respir Dis* 1986; 133(5):792–796.
 22. Chastre J, Trouillet JL, Vuagnat A, Joly-Guillou ML, Clavier H, Dombret MC *et al.*; Nosocomial pneumonia in patients with acute respiratory distress syndrome. *Am J Respir Crit Care Med* 1998; 157(4): 1165–1172.
 23. Delclaux C, Roupie E, Blot F, Brochard L, Lemaire F, Brun-Buisson C; Lower respiratory tract colonization and infection during severe acute respiratory distress syndrome: incidence and diagnosis. *Am J Respir Crit Care Med* 1997; 156(4):1092–1098.
 24. Hayon J, Figliolini C, Combes A, Trouillet JL, Kassis N, Dombret MC *et al.*; Role of Serial Routine Microbiologic Culture Results in the Initial Management of Ventilator-associated Pneumonia. *Am J Respir Crit Care Med* 2002; 165(1): 41–46.
 25. Markowicz P, Wolff M, Djedaini K.A.M.E.L, Cohen Y, Chastre J, Delclaux C, *et al.*; Multicenter prospective study of ventilator-associated pneumonia during acute respiratory distress syndrome. Incidence, prognosis, and risk factors. ARDS Study Group. *Am J Respir Crit Care Med* 2000; 161(6):1942–1948.